Tesamorelin (Egrifta SV): A GHRH Analog for HIV-Associated Visceral Fat Reduction

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health offers tesamorelin-related telehealth services for FDA-approved indications. Tesamorelin (Egrifta SV) is a prescription medication available by prescription only. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider. For full prescribing information, see the Egrifta SV label on DailyMed.

The liver was never supposed to fill with fat. Neither was the space between the organs. Yet for many people living with HIV on antiretroviral therapy, visceral adiposity (dense fat accumulating inside the abdominal cavity and within the liver itself) has become one of the most consequential metabolic consequences of long-term treatment. The condition has a name, HIV-associated lipodystrophy, and for over a decade it had no effective pharmacologic answer.

Tesamorelin changed that. Here is how this growth hormone-releasing hormone analog works at the molecular level, what the pivotal clinical trials showed, and which biomarkers to track before and during use.

Key Takeaways

• Regulatory Status: FDA-approved since 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy (Egrifta; reformulated as Egrifta SV in 2019). As of April 2026, tesamorelin is an FDA-approved prescription medication.
• Research Stage: Approved and marketed; Phase III and extension trial data available in HIV lipodystrophy; off-label research ongoing in non-HIV visceral fat and liver fat contexts.
• Availability: Not available through Superpower. Tesamorelin (Egrifta SV) is FDA-approved and available by prescription through licensed providers for HIV-associated lipodystrophy; availability may vary by state.
• Prescribing information: View full prescribing information on DailyMed (Egrifta SV) · PubChem compound record (CID 16137828)
• How it works: Binds GHRH receptors in the pituitary to stimulate pulsatile growth hormone secretion, which in turn increases IGF-1 and shifts adipose metabolism toward visceral fat reduction.
• What the research shows: In two pivotal Phase III trials reported by Falutz and colleagues, tesamorelin 2 mg daily reduced visceral adipose tissue by approximately 15% versus placebo over 26 weeks (treatment effect -15.4%, p<0.001 in pooled analysis, n=806), with liver fat reductions (-2.9% absolute lipid-to-water ratio, p=0.003) documented in a 2014 JAMA trial by Stanley and colleagues.

Tesamorelin (brand name Egrifta SV; the original Egrifta was reformulated in 2019) is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH). The endogenous form of GHRH, a 44-amino acid peptide, is unstable in circulation and degrades rapidly. Tesamorelin retains the full GHRH(1-44) sequence but adds a trans-3-hexenoic acid moiety at the N-terminus, which stabilizes the molecule without altering receptor binding or downstream signaling. A 2015 population pharmacokinetic and pharmacodynamic analysis by González-Sales and colleagues in the Journal of Pharmacokinetics and Pharmacodynamics modeled tesamorelin 1-2 mg daily subcutaneous dosing over 14 days in 41 Phase I participants and confirmed that the time course of GH and IGF-1 concentrations was well predicted by a sequential PK/PD model, with no significant effect of age, body weight, BMI, sex, or race on drug response. A subsequent 2011 review by Dhillon in Drugs synthesized the regulatory record that led to approval. The result is a compound that mimics endogenous GHRH activity with a pharmacokinetic profile suited to once-daily subcutaneous dosing.

How Tesamorelin Works in the Body

GHRH receptor binding and pulsatile GH release

Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland. This binding triggers the release of endogenous growth hormone in a pulsatile pattern that mirrors the physiological GH secretion the body normally produces in response to endogenous GHRH. The distinction from exogenous GH administration is mechanistically important: tesamorelin does not introduce GH directly but amplifies the pituitary's own secretory function. A 2011 study by Stanley and colleagues in the Journal of Clinical Endocrinology and Metabolism randomized 13 healthy men to tesamorelin 2 mg subcutaneously once daily for 2 weeks with frequent overnight GH sampling and found that mean overnight GH rose by +0.5 ± 0.1 μg/L (p = 0.004) while preserving the pulsatile architecture of GH secretion rather than producing the sustained supraphysiological elevations associated with exogenous GH injection.

IGF-1 elevation and downstream metabolic effects

Growth hormone released in response to tesamorelin stimulates the liver and other tissues to produce insulin-like growth factor 1 (IGF-1). IGF-1 is the primary mediator of many GH-dependent metabolic effects, including lipolysis in visceral adipose tissue. IGF-1 promotes the breakdown of stored triglycerides in visceral fat depots through hormone-sensitive lipase activation, preferentially mobilizing the metabolically active fat that accumulates around the organs. This mechanism explains why the visceral fat reductions seen in tesamorelin trials are regionally specific: the drug does not produce global fat loss across all depots. Subcutaneous fat in the limbs is largely unaffected, which distinguishes tesamorelin's action from the peripheral lipoatrophy pattern that many people with HIV-associated lipodystrophy also experience. IGF-1 is the primary monitoring biomarker for tesamorelin response and safety.

Stabilization through trans-3-hexenoic acid modification

Endogenous GHRH(1-44) has a plasma half-life measured in minutes because it is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) at the N-terminus. Tesamorelin's trans-3-hexenoic acid modification at that same N-terminal position creates steric hindrance that blocks DPP-IV cleavage while leaving the receptor-binding portions of the molecule intact. A 2025 review by Schally and colleagues in Reviews in Endocrine and Metabolic Disorders surveyed the development of GHRH analogs including tesamorelin, documenting how this chemical stabilization strategy was central to making a peripherally administered GHRH analog pharmacologically viable. The modification does not change the fundamental receptor pharmacology. Tesamorelin binds and activates the GHRH receptor with affinity comparable to the endogenous peptide.

Effects on liver fat and hepatic metabolism

Beyond visceral adipose tissue, tesamorelin has been studied for its effects on ectopic fat deposition in the liver. In people with HIV-associated lipodystrophy, non-alcoholic fatty liver disease (NAFLD) is more prevalent than in the general population and tends to be more severe. The mechanism connecting GHRH stimulation to hepatic fat reduction likely involves both reduced delivery of free fatty acids from visceral depots to the liver via portal circulation and direct GH-mediated effects on hepatic lipid metabolism. A 2017 secondary analysis by Fourman, Czerwonka, and colleagues in AIDS of the two pivotal Phase III trials (n=806) documented that HIV patients who responded to tesamorelin with VAT reduction had significantly greater improvements in ALT (-8.9 ± 22.6 vs. +1.4 ± 34.7 U/L, p = 0.004) and AST (-3.8 ± 12.9 vs. +0.4 ± 22.4 U/L, p = 0.04) at 26 weeks among those with baseline elevated transaminases, with improvements persisting at 52 weeks — providing an early signal of hepatic benefit. A subsequent 2021 analysis by Fourman and colleagues in Clinical Infectious Diseases characterized clinical predictors of fibrosis presence and progression in HIV-associated NAFLD, and a separate 2021 study by Lake and colleagues in AIDS found that tesamorelin improves fat quality independent of changes in fat quantity. An earlier contextual paper by Torriani and colleagues (2003) in the Journal of Applied Physiology had established that CT-measured psoas muscle attenuation indicates intramuscular fat accumulation in HIV-lipodystrophy, framing why these fat-quality endpoints matter clinically.

What the Research Shows About Effectiveness

Pivotal Phase III trials: visceral fat reduction in HIV lipodystrophy

The foundational evidence for tesamorelin comes from two multicenter Phase III randomized controlled trials. Results were pooled and analyzed in a 2010 pooled analysis by Falutz, Mamputu, and colleagues in the Journal of Clinical Endocrinology and Metabolism, which combined 806 ART-treated adults with HIV-associated abdominal fat accumulation (tesamorelin n=543, placebo n=263) across two double-blind, placebo-controlled Phase III trials. Participants received tesamorelin 2 mg subcutaneously once daily or placebo for 26 weeks, followed by a 26-week safety extension. Visceral adipose tissue measured by computed tomography at L4 decreased by a mean of 24 ± 41 cm² in the tesamorelin arm versus an increase of 2 ± 35 cm² in placebo (treatment effect approximately -15.4%, p < 0.001), with concurrent reductions in fasting triglycerides (-37 ± 139 mg/dL vs. +6 ± 112 mg/dL, p < 0.001) and improvements in the cholesterol/HDL ratio (p < 0.001). Tesamorelin was generally well tolerated, with no clinically meaningful differences in glucose parameters between arms in this pooled analysis. The earlier pivotal 2007 trial by Falutz, Allas, and colleagues in the New England Journal of Medicine enrolled 412 HIV patients with excess abdominal fat in a double-blind, placebo-controlled randomized design and documented a 15.2% reduction in visceral adipose tissue with tesamorelin 2 mg subcutaneously daily for 26 weeks versus a 5.0% increase with placebo (p < 0.001), along with significant improvements in triglycerides and cholesterol ratios (both p < 0.001), with no significant differences in glycemic measures and adverse event rates broadly comparable between arms — the trial that served as the basis for FDA approval. A 52-week extension study by Falutz, Potvin, Mamputu, and colleagues in the Journal of Acquired Immune Deficiency Syndromes in 2010 followed 404 HIV patients across two sequential 6-month phases and confirmed sustained visceral adipose tissue reduction at 12 months (p < 0.001) with parallel improvements in trunk fat (p < 0.001), waist circumference (p = 0.02), and IGF-1 (p < 0.001), while showing that VAT returned toward baseline in participants switched to placebo in the second phase. That finding has direct implications for long-term treatment decisions. A separate long-term safety report by Falutz and colleagues in AIDS in 2008 documented extended safety outcomes in the same HIV-infected population with abdominal fat accumulation.

Visceral fat, liver fat, and metabolic profile: the Stanley JAMA trial

The most comprehensive single trial documenting both visceral adipose tissue and liver fat outcomes was a 2014 double-blind, placebo-controlled trial by Stanley, Feldpausch, and colleagues in JAMA, which randomized 50 HIV patients with abdominal fat accumulation (tesamorelin n=28, placebo n=22) to tesamorelin 2 mg subcutaneously daily or placebo for 6 months. VAT decreased by 34 cm² with tesamorelin versus increasing by 8 cm² with placebo (net treatment effect -42 cm², p = 0.005), and liver fat fraction measured by magnetic resonance spectroscopy fell by 2.0% with tesamorelin versus increasing by 0.9% with placebo (net -2.9%, p = 0.003). A transient 2-week fasting glucose increase favored placebo (p = 0.03) but resolved by 6 months, with no significant between-group glucose differences at study end. A companion metabolic analysis by Stanley and colleagues published in Clinical Infectious Diseases in 2012 showed that the visceral fat reduction achieved with tesamorelin was associated with improvements in fasting triglycerides, with directional improvements in HbA1c and other metabolic markers in some analyses, though glucose tolerance changes required careful monitoring given GH's known counter-regulatory effects on insulin sensitivity. A separate analysis by Stanley and colleagues in AIDS in 2011 pooled 410 HIV-infected adults with excess abdominal fat (273 tesamorelin, 137 placebo) from the pivotal Phase III trials and found that tesamorelin 2 mg subcutaneously daily for 26 weeks produced a greater reduction in tissue plasminogen activator antigen (-2.2 ± 2.5 vs. -1.6 ± 2.9 ng/mL, p < 0.05) that correlated with the visceral adipose tissue reduction, providing a link between VAT loss and improvements in cardiovascular inflammatory risk markers.

Liver fat and NAFLD in HIV: the Lancet HIV and JCI Insight trials

Two subsequent trials specifically investigated tesamorelin in HIV-associated NAFLD. A 2019 multicenter randomized, double-blind, placebo-controlled trial by Stanley, Fourman, and colleagues in Lancet HIV enrolled 61 adults with HIV and NAFLD (30 tesamorelin, 30 placebo; 1 withdrew) and assigned them to tesamorelin 2 mg daily or placebo for 12 months followed by 6 months open-label. Liver fat fraction fell by 4.1% absolute (95% CI -7.6 to -0.7, p = 0.018) and 37% relative (95% CI -67 to -7, p = 0.016), with 35% of the tesamorelin group achieving resolution (HFF < 5%) versus 4% with placebo (p = 0.0069). Injection site reactions were more common in the tesamorelin arm but none were judged serious, and glucose and HbA1c did not differ significantly between groups at 12 months. A parallel mechanistic study by Fourman and colleagues published in JCI Insight in 2020 examined hepatic transcriptomic signatures in HIV-associated NAFLD and found that tesamorelin reversed several gene expression patterns associated with hepatic inflammation and fibrosis risk, providing a molecular basis for the observed histological improvements. A 2021 analysis by Stanley and colleagues in Clinical Infectious Diseases drew from the 61-participant HIV-NAFLD cohort on tesamorelin 2 mg daily or placebo for 12 months and documented that tesamorelin significantly reduced 13 circulating immune-activation proteins (including chemokines and T-cell markers, FDR < 0.1 across 92 biomarkers) with parallel down-regulation of hepatic immune pathways, suggesting a mechanism beyond simple fat reduction.

Non-HIV visceral fat: off-label evidence in obese adults

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. A 2012 trial by Makimura, Feldpausch, and colleagues in the Journal of Clinical Endocrinology and Metabolism randomized 60 abdominally obese non-HIV adults with reduced GH secretion to tesamorelin 2 mg daily or placebo for 12 months in a double-blind, placebo-controlled design, and documented that VAT decreased by 16 ± 9 cm² with tesamorelin versus an increase of 19 ± 9 cm² with placebo (p = 0.003) — representing the primary published evidence for off-label use in a general population context. These data inform clinical discussion of off-label use but do not constitute an FDA-approved indication. No other use has been approved by the FDA, and the safety and efficacy for other uses have not been established through adequate and well-controlled clinical trials. Any off-label use is the independent clinical judgment of the prescribing physician.

Body composition and muscle quality

A 2019 secondary exploratory analysis by Adrian, Scherzinger, and colleagues in the Journal of Frailty and Aging pooled 341 participants from two randomized trials (193 tesamorelin VAT responders, 148 placebo) and found that tesamorelin-treated responders showed increased muscle density across all four truncal muscle groups (coefficients 1.56–4.86 Hounsfield units, p < 0.005) and increased lean muscle area (0.64–1.08 cm², p < 0.005), suggesting that GH axis stimulation has effects on skeletal muscle quality beyond the well-characterized visceral adipose tissue reduction. The post-hoc design and conditioning on VAT response limit causal inference. A 2014 study by Makimura, Murphy, Feldpausch, and Grinspoon in the Journal of Clinical Endocrinology and Metabolism examined phosphocreatine recovery as a marker of mitochondrial function in 39 obese non-HIV adults with reduced GH secretion treated with tesamorelin 2 mg daily or placebo for 12 months and found a significant positive correlation between IGF-1 increases and phosphocreatine recovery improvements (R = 0.56, p = 0.01, strengthening to R = 0.71, p = 0.03 within the tesamorelin arm alone), with tesamorelin producing greater IGF-1 increase than placebo (102.9 ± 31.8 vs. 22.8 ± 8.9 μg/L, p = 0.02). The modest sample size tempers these mechanistic inferences.

Safety in people with type 2 diabetes

Because GH has counter-regulatory effects on insulin sensitivity, the safety of tesamorelin in individuals with pre-existing glucose dysregulation is a clinically relevant question. A 2017 randomized placebo-controlled trial by Clemmons, Miller, and Mamputu in PLoS ONE enrolled 53 adults with type 2 diabetes across three arms (placebo, tesamorelin 1 mg, tesamorelin 2 mg) over 12 weeks and found no significant between-group differences in relative insulin response or fasting glucose at week 12. The 2 mg arm showed significant reductions in total and non-HDL cholesterol (p < 0.05 vs. placebo), suggesting that over this short horizon glycemic control was not worsened in a T2D population — the primary dedicated safety reference for tesamorelin in people with pre-existing glucose dysregulation, though the short duration and small sample limit conclusions about longer-term glycemic effects.

Contemporary ART populations

Most pivotal tesamorelin trials enrolled participants on older antiretroviral regimens. A 2024 randomized placebo-controlled trial by Russo, Ockene, and colleagues in AIDS addressed this gap, enrolling 38 people with HIV on integrase strand transfer inhibitor (INSTI)-based regimens with metabolic dysfunction-associated steatotic liver disease and randomizing them to tesamorelin 2 mg subcutaneously daily (n = 15 completers) or placebo (n = 16 completers) for 12 months. Visceral fat decreased by a median of 25 cm² in the tesamorelin arm versus an increase of 14 cm² with placebo (p = 0.001), hepatic fat fraction fell by a median of 4.2% versus 0.5% (p = 0.01), and the trunk-to-appendicular fat ratio shifted favorably (p = 0.03), with similar rates of adverse events including hyperglycemia between groups. The small sample size limits generalizability, but the trial confirms tesamorelin retains efficacy in the contemporary INSTI-treated population. A 2025 randomized trial by Ellis and colleagues in the Journal of Infectious Diseases separately examined tesamorelin's effects on neurocognitive outcomes in 73 virally suppressed people with HIV and abdominal obesity, randomized 3:2 to tesamorelin 2 mg subcutaneously daily or standard of care for 6 months. The tesamorelin group showed a trend toward improved neurocognitive performance (mean change 0.146, 95% CI -0.002 to 0.294, p = 0.060) and greater waist circumference reduction than standard care, but the between-group difference in cognitive performance was not statistically significant (p = 0.673) — a null result on the cognitive endpoint that tempers any claim of neurocognitive benefit from tesamorelin in this population.

Tesamorelin vs. Sermorelin and Exogenous GH: Key Differences

Tesamorelin, sermorelin, and exogenous growth hormone all elevate circulating GH and IGF-1, but they differ in mechanism, evidence base, regulatory status, and risk profile in ways that matter clinically.

Tesamorelin is a full-length GHRH(1-44) analog, chemically stabilized for subcutaneous use, with the only substantial body of randomized controlled trial data in the GHRH peptide class. It preserves physiological pulsatile GH secretion and operates through the pituitary's own feedback machinery, meaning the hypothalamic-pituitary axis continues to modulate GH output in response to other signals. This is the fundamental physiological advantage of the GHRH-agonist approach over direct GH injection.

Sermorelin is a truncated GHRH analog comprising only the first 29 amino acids (GHRH 1-29), the minimum fragment required for full GHRH receptor activation. Sermorelin lacks tesamorelin's N-terminal stabilization modification, meaning it is more rapidly degraded by DPP-IV in vivo. A comparison GHRH analog study by Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006 examined CJC-1295, another GHRH analog with drug affinity complex technology, and documented prolonged GH and IGF-1 secretion in healthy adults as a mechanistic reference for the GHRH class. Sermorelin is not FDA-approved and has a substantially smaller clinical trial database than tesamorelin. The clinical evidence for tesamorelin's visceral fat and liver fat effects (multiple Phase III RCTs in HIV lipodystrophy) has no equivalent in the sermorelin literature.

Exogenous GH administration bypasses pituitary feedback entirely, suppressing endogenous GH secretion through somatostatin feedback and GHRH downregulation. Supraphysiological GH exposure is associated with a higher rate of glucose dysregulation, edema, carpal tunnel syndrome, and arthralgias than pituitary-stimulating approaches. The GHRH-analog approach produces GH within the physiological range modulated by native feedback, which is the mechanistic rationale for a more favorable metabolic safety profile.

Side Effects and What to Expect

The most common side effects of tesamorelin are consistent across the Phase III trials and relate to GH-mediated effects on fluid balance and soft tissue, as well as local reactions at the injection site. The glucose-related effects require particular attention given GH's counter-regulatory role in insulin metabolism.

Common side effects:

• Injection-site reactions (erythema, pruritis, pain, and swelling at the subcutaneous injection site): reported in approximately 25 to 35 percent of participants in pivotal trials, typically mild and transient
• Peripheral edema: fluid retention, particularly in the extremities, consistent with GH-mediated effects on sodium and water reabsorption
• Arthralgia and myalgia: joint and muscle discomfort, related to GH-stimulated tissue changes, typically mild to moderate
• Paresthesia: tingling or numbness in the extremities, consistent with fluid-related pressure effects
• Nausea: reported in a subset of participants, typically mild

Metabolic effects requiring monitoring:

• Glucose dysregulation: GH has counter-regulatory effects on insulin sensitivity, and the FDA-approved label reports modest increases in fasting glucose and HbA1c during tesamorelin therapy. The Clemmons 2017 PLoS ONE trial in 53 adults with type 2 diabetes over 12 weeks found no significant between-group differences in fasting glucose or insulin response, though longer-horizon data in glucose-dysregulated populations remain limited. Providers track fasting glucose and HbA1c during therapy.
• IGF-1 elevation above the reference range: IGF-1 may rise substantially with tesamorelin use. Sustained supraphysiological IGF-1 carries theoretical concern for tissue proliferation; providers monitor IGF-1 levels and may adjust or discontinue if levels exceed the age-appropriate reference range.

Less common but reported:

• Hypersensitivity reactions (urticaria, rash, flushing): rare; discontinue and consult your provider promptly if systemic allergic signs appear
• Fluid retention in the face: facial puffiness, less common than peripheral edema
• Carpal tunnel syndrome: wrist pain and paresthesia consistent with soft tissue fluid accumulation in the carpal tunnel, a recognized GH-class effect; providers assess if wrist symptoms develop

Providers monitor glucose tolerance and IGF-1 at defined intervals during therapy. If glucose dysregulation develops or IGF-1 rises above age-appropriate reference ranges, dose adjustment or discontinuation is standard clinical practice. Patients with pre-existing diabetes or impaired glucose tolerance require closer monitoring and potentially more frequent glucose testing.

Who Is Tesamorelin Typically Prescribed For?

HIV-associated lipodystrophy with excess abdominal fat

Tesamorelin is FDA-approved specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Providers typically consider tesamorelin for adults with confirmed HIV who are on stable antiretroviral therapy and have developed clinically significant visceral adiposity, defined by patient history, physical examination, and ideally CT imaging to characterize the distribution of adipose tissue. The approved indication does not require a minimum duration of HIV infection or antiretroviral use, but the clinical picture of lipodystrophy-associated visceral fat accumulation should be established before initiating therapy. Patient-reported body image concerns associated with abdominal protrusion are a recognized component of the indication. Lipodystrophy-associated peripheral lipoatrophy in the limbs and face is NOT an approved indication for tesamorelin.

Off-label: non-HIV visceral fat and NAFLD

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. The 2012 Makimura trial in non-HIV adults with abdominal obesity and the broader hepatic fat literature inform discussions of off-label use in contexts such as visceral adiposity with GH deficiency, NAFLD without HIV, and metabolic syndrome-associated fat distribution. Any such prescribing represents the independent clinical judgment of the provider and is not an FDA-approved indication. The safety and efficacy in these populations have not been established through adequate and well-controlled trials sufficient for regulatory approval.

Who Should Not Take Tesamorelin

A licensed provider will conduct a full clinical evaluation before prescribing. The following represent contraindications or conditions requiring additional scrutiny based on the FDA-approved prescribing information and the clinical trial safety database:

• Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma: tesamorelin requires an intact pituitary to generate GH secretion in response to GHRH receptor stimulation, and damage to this axis eliminates the pharmacological basis for the drug's effect
• Active malignancy or history of malignancy: IGF-1 elevation may have proliferative effects in the context of existing cancer, and providers carefully assess oncologic history before prescribing any compound that raises IGF-1
• Pregnancy: tesamorelin should not be used during pregnancy; women of childbearing potential should use effective contraception
• Active proliferative or severe non-proliferative diabetic retinopathy: GH elevation may worsen retinal complications in individuals with advanced diabetic eye disease
• Known hypersensitivity to tesamorelin or any of its components, including mannitol
• Pre-existing diabetes or impaired glucose tolerance: not a contraindication per se, but requires additional monitoring and a provider assessment of whether the visceral fat benefit outweighs the glucose risk for the individual patient

This is not an exhaustive list of contraindications or precautions. A licensed provider will evaluate the complete clinical picture, including current medications, comorbidities, and baseline metabolic status, before determining eligibility.

What to Test Before Starting Tesamorelin

Establishing a comprehensive metabolic and hormonal baseline before initiating tesamorelin is clinically essential. The drug's mechanism (pituitary GH stimulation leading to IGF-1 elevation and visceral fat mobilization) creates predictable biomarker changes that require pre-treatment context to interpret safely. Several of these markers are also safety monitoring parameters during therapy.

• IGF-1: The primary pharmacodynamic monitoring marker for tesamorelin. IGF-1 reflects integrated GH secretion over days to weeks. Baseline IGF-1 establishes the starting point against which treatment-related increases are assessed; values should remain within the age- and sex-appropriate reference range during therapy. Providers check IGF-1 at baseline and at regular intervals during use.
• Fasting glucose: GH has counter-regulatory effects on insulin sensitivity. Baseline fasting glucose documents pre-treatment glycemic status and is the reference against which any glucose changes during therapy are interpreted. Individuals with pre-existing hyperglycemia require closer post-initiation monitoring.
• Hemoglobin A1c (HbA1c): Provides a 90-day average of glycemic control. Baseline HbA1c is essential for identifying pre-existing glucose dysregulation that would warrant additional monitoring or a risk-benefit discussion before starting. Providers repeat HbA1c during therapy to detect treatment-related changes in long-term glycemic control.
• Fasting insulin: Together with fasting glucose, a baseline insulin level enables calculation of insulin resistance proxies (HOMA-IR) and provides a more complete picture of glucose metabolism at baseline. This context is particularly valuable if HbA1c is borderline or if the patient has other metabolic risk factors. See the blood sugar and insulin sensitivity biomarker guide for interpretation context.
• Triglycerides: Visceral adiposity is strongly associated with elevated triglycerides, and tesamorelin has been shown to reduce fasting triglycerides as a secondary outcome in several trials. A baseline triglyceride level captures the starting metabolic profile and enables tracking of this favorable secondary effect.
• Liver enzymes (ALT, AST, GGT): Visceral fat accumulation in HIV lipodystrophy is frequently accompanied by elevated liver enzymes reflecting NAFLD or NASH. Baseline liver function tests document pre-treatment hepatic status and provide context for any changes during therapy. The Fourman 2017 AIDS trial documented liver enzyme improvements with tesamorelin use; detecting this benefit requires a pre-treatment baseline. The liver health biomarkers guide covers these markers in depth.
• Comprehensive metabolic panel: Covers kidney function (creatinine, BUN, eGFR), electrolytes, and liver markers in a single draw. Establishes baseline renal and metabolic safety parameters and is standard before initiating any prescription compound.
• Fasting lipid panel: HIV and antiretroviral therapy independently alter lipid profiles. Baseline total cholesterol, LDL, HDL, and triglycerides establish the cardiovascular risk context and enable tracking of any lipid-related changes during tesamorelin use.
• Fasting C-peptide (for diabetes screening): In individuals with borderline glucose values, a fasting C-peptide can help distinguish between insulin secretory insufficiency and insulin resistance, informing whether tesamorelin's glucose-elevating potential poses a meaningful additional risk for the individual patient.

What Your Bloodwork May Show While on Tesamorelin

When tesamorelin is producing its intended effect, the biomarker changes follow a predictable pattern. IGF-1 should rise from baseline, reflecting increased pituitary GH output; providers expect to see IGF-1 increase and monitor that it stays within the age- and sex-appropriate reference range rather than exceeding it. Fasting triglycerides should trend downward over the course of treatment, consistent with the secondary lipid improvements documented in multiple Phase III trials. Liver enzymes (ALT, AST, GGT) may improve in participants who had elevated baseline values reflecting hepatic fat accumulation, as documented in the Fourman 2017 trial. HbA1c and fasting glucose may edge upward modestly in some individuals, consistent with GH's counter-regulatory metabolic effects; these changes are typically small in people without pre-existing glucose dysregulation but warrant monitoring. Body composition changes (reduced abdominal girth and improved trunk fat ratio) are clinical outcomes tracked in parallel with bloodwork. Without a pre-treatment baseline for each of these markers, the data from follow-up labs is difficult to interpret in context.

That principle, measuring before initiating and continuing to track how values respond, is foundational to Superpower's approach to preventive health. Objective biomarker data, established before any medication change and tracked systematically afterward, is what allows providers and patients to evaluate whether a treatment is doing what it is supposed to do.

IMPORTANT SAFETY INFORMATION

Tesamorelin (Egrifta SV) is an FDA-approved prescription medication indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Superpower Health does not prescribe, sell, compound, or facilitate access to tesamorelin; this page is provided for educational and informational purposes only. All prescribing represents the independent clinical judgment of the licensed provider.

Contraindications: Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, radiation therapy of the head, or head trauma); active malignancy; pregnancy; active proliferative or severe non-proliferative diabetic retinopathy; known hypersensitivity to tesamorelin or any of its excipients including mannitol.

Warnings and precautions: Fluid retention (edema, arthralgias, carpal tunnel syndrome); glucose intolerance and diabetes mellitus (monitor glucose and HbA1c; use with caution in patients with pre-existing glucose dysregulation); IGF-1 elevation above the age-appropriate reference range (monitor IGF-1 levels during therapy); neoplasms (GH and IGF-1 may promote growth of existing malignancies; assess carefully in patients with oncologic history); hypersensitivity reactions including urticaria and rash.

Common side effects: Injection-site reactions (erythema, pruritis, pain, swelling), peripheral edema, arthralgia, paresthesia, nausea, myalgia.

Visceral fat returns toward baseline after discontinuation of tesamorelin. Long-term IGF-1 monitoring is standard practice during treatment. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Use in non-HIV populations or for indications other than excess abdominal fat in HIV lipodystrophy is not FDA-approved; such use is the independent clinical judgment of the prescribing provider. Availability may vary by state.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Additional Questions

Does tesamorelin cause side effects?

The most commonly reported side effects in Phase III trials were injection-site reactions (erythema, pruritis, pain), peripheral edema, arthralgia, paresthesia, and nausea. These are broadly consistent with GH-class effects and local subcutaneous injection reactions. Injection-site reactions were the most frequently reported individual adverse event. Glucose dysregulation and IGF-1 elevation above the reference range are metabolic effects requiring monitoring. Hypersensitivity reactions are rare but warrant prompt provider contact.

How long does tesamorelin need to be taken for the effect to persist?

The 52-week extension trial by Falutz, Potvin, Mamputu, and colleagues confirmed that visceral fat reduction is sustained with continued tesamorelin use and that visceral adipose tissue returns toward baseline values after discontinuation. This indicates that the medication requires continued use to maintain the visceral fat reduction effect. Providers assess the risk-benefit balance of long-term use on an individual basis, taking into account metabolic monitoring results, IGF-1 levels, and overall clinical response.

What biomarkers should I get before starting tesamorelin?

The core pre-treatment panel includes IGF-1, fasting glucose, HbA1c, fasting triglycerides, liver enzymes (ALT, AST, GGT), and a comprehensive metabolic panel. Fasting insulin adds useful context on pre-existing insulin resistance. For a deeper picture of metabolic risk at baseline, the blood sugar and insulin sensitivity biomarker guide and the metabolic health biomarker testing guide provide interpretation context for these values. A provider will determine which specific tests are appropriate based on your clinical presentation and existing lab history.